---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-002772"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:28:32.449651+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Guidance, and Preferred Stock Conversion

## Summary
- Preliminary 2025 thyroid testing revenue of ~$34-35M, up 21% over prior year.
- Company initiates 2026 revenue guidance of ~$40M, representing 16% growth in thyroid testing.
- All outstanding Series C Preferred Stock converted into common stock at $2.02 per share, issuing ~23.3M shares.
- Company is debt-free with positive net income and EBITDA, plans to seek uplisting to Nasdaq in 2026.
- Following conversion, pro forma basic shares outstanding ~27.7M; 1315 Capital owns ~34%, Ampersand owns ~50%.

## SEC filing metadata
- accession: 0001493152-26-002772
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315226002772/0001493152-26-002772-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315226002772/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-002772
- JSON: https://secwatch.observer/filing/0001493152-26-002772.json
- Plain text: https://secwatch.observer/filing/0001493152-26-002772.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.